Zinc-finger protein 217 (ZNF217) is a Kruppel-like zincfinger protein located at 20q13.2, within a region of recurrent maximal amplification. Here, we demonstrate that ZNF217 is a transcriptional repressor protein and report the purification and characterization of a ZNF217 complex. The purified ZNF217 complex consists of approximately six proteins and contains the transcriptional co-repressors CoREST, BHC110/LSD1, histone deacetylase (HDAC) 2 and C-terminal binding protein (CtBP1). The purified ZNF217 complex possesses deacetylase activity as well as lysine 4 histone H3-specific demethylase activity that is most likely mediated by the BHC110/LSD1 component. To determine if ZNF217 is a sequence-specific binding protein, we have made use of cyclic amplification and selection of targets (CAST) assay and identify for the first time a ZNF217 DNA consensus recognition sequence (CRS) that is highly conserved in the human E-cadherin promoter. Chromatin immunoprecipitation (ChIP) experiments demonstrate that ZNF217, as well as the other components of the ZNF217 complex, are found on the region of the proximal E-cadherin promoter that contains the identified ZNF217 CRS in vivo. Using a combination of transient transfections and small interfering RNA, we demonstrate that ZNF217 represses the E-cadherin promoter. Collectively, our results implicate ZNF217 and its associated proteins in a novel pathway that may have profound effects on cancer progression.
Introduction
Zinc-finger protein 217 (ZNF217) is a candidate oncogene found at 20q13.2, a region that is frequently amplified in breast cancer and is associated with aggressive tumour behaviour and poor clinical prognosis (Collins et al., 1998 (Collins et al., , 2001 Tanner et al., 1994 Tanner et al., , 1995 . ZNF217 contains eight Cys 2 -His 2 zinc-fingers and belongs to the large family of Kruppel-like transcription factors (Iuchi, 2001) . Although the exact function of ZNF217 has not been established, biochemical purification studies have found ZNF217 as a constituent of several related transcriptional co-repressor complexes that contain the histone deacetylases (HDAC1 and HDAC2) (You et al., 2001; Hakimi et al., 2003; Lee et al., 2005) . ZNF217 has also been identified as a component of the C-terminal binding protein (CtBP1) complex (Shi et al., 2003) . CtBP1 can serve as a corepressor for several classes of transcription factors in both an HDAC-dependent and -independent fashion (Chinnadurai, 2002) . Chromatin immunoprecipitation (ChIP) assays have shown that CtBP1 and several of its associated proteins target the E-cadherin promoter in various breast cancer cell lines (Shi et al., 2003) . Ecadherin is a tumour suppressor and a critical component of cellular adhesion junctions required for normal epithelial formation and integrity (Thiery, 2002) .
In the present study, we demonstrate that ZNF217 functions as a transcriptional repressor that associates with a core group of proteins including the co-repressors CtBP1 and CoREST, HDAC2, and the flavin adenine dinucleotide (FAD)-binding protein BHC110/LSD1. Second, we have identified a core DNA-binding domain within ZNF217 and, using cyclic amplification and selection of targets (CAST) analysis, define a consensus recognition sequence (CRS) that is highly conserved in the E-cadherin proximal promoter. Using a combination of transient transfection, siRNA and ChIP analysis, we demonstrate that ZNF217 is capable of mediating repression of the E-cadherin promoter. Collectively, our results define a novel pathway that targets the ZNF217 complex to the proximal promoter of the E-cadherin gene. Importantly, our studies suggest that amplification of ZNF217, as seen in many breast tumours, may result in aberrant targeting of corepressors to specific genes such as E-cadherin.
Results

ZNF217 is a transcriptional repressor protein
To ascertain whether ZNF217 possesses transcriptional activity, full-length ZNF217 was tethered to the DNA-binding domain of Gal4 and co-transfected with a luciferase reporter plasmid containing Gal4-binding sites. Transfection of Gal4ZNF217 resulted in a consistent 5-10-fold repression of the reporter gene ( Figure 1 ). Deletion analysis of various regions of ZNF217 fused to Gal4 indicated that the repressor activity was confined to two regions located within the carboxy terminus of the protein. To determine if the repressor activity is mediated by HDACs, transfected cells were treated with the HDAC inhibitor trichostatin A (TSA) before measuring luciferase activity. This resulted in approximately 50% inhibition of the repressor activity of the full-length ZNF217 protein. Interestingly, the more amino-terminal repressor domain (aa 528-789) was inhibited by TSA whereas the major repression domain (aa 751-1048), located within the extreme carboxy terminus, was not. These results suggest that the ZNF217 mediates repression in both an HDAC-dependent and -independent manner.
Purification of a ZNF217 repressor complex
To identify proteins that may mediate the repressive function of ZNF217, we purified an endogenous ZNF217 complex from HeLa cell nuclear extracts by affinity chromatography using an aZNF217 antibody crosslinked to protein A Sepharose. SDS-polyacrylamide gel electrophoresis (PAGE) analysis followed by silver staining revealed several polypeptides that copurified with ZNF217, which were not present in the control immunopurification (Figure 2a) . Several of the immunopurified proteins were excised, subjected to ingel trypsinization and sequenced by mass spectrometry. Their identity is indicated in Figure 2a , with the exception of CtBP1, which was identified by Western blotting. ZNF217 was identified as a doublet migrating at approximately 120-130 kDa. In addition, we consistently identified stoichiometric amounts of the transcriptional co-repressor CoREST, the FAD-binding protein BHC110/LSD1, which has recently been shown to possess histone demethylase activity, and the HDAC2. The association of CoREST, BHC110/LSD1 and HDAC2 in the purified ZNF217 complex was confirmed by Western blotting (Figure 2b ) as well as co-immunoprecipitations using specific antibodies ( Figure 2c ).
As HDAC2 and BHC110/LSD1 possess HDAC and demethylase activity, respectively, we examined whether these specific activities are also associated with the purified ZNF217 complex. We observed that the ZNF217 complex can deacetylase core histones and this deacetylation is blocked by the deacetylase inhibitor TSA (Figure 2d ). Histone demethylase activity was (Figure 2e ). Collectively, our results support the hypothesis that both deacetylase and demethylase activities are associated with ZNF217.
ZNF217 interacts directly with both CtBP1 and CoREST
Biochemical experiments were conducted to further characterize the interaction of CoREST, CtBP1 and ZNF217. First, co-immunoprecipitation experiments were performed using MCF-7 cells overexpressing epitope-tagged CtBP1, ZNF217 and CoREST. These experiments indicated that ZNF217 could be coimmunoprecipitated in the presence of either CtBP1 or CoREST ( Figure 3a ). Second, in vitro pulldown assays indicate that the predominant CtBP1 interaction domain resides in the carboxy terminus, which contains the major repressor domain within ZNF217 and is insensitive to TSA (Figure 3b ). In contrast, the predominant CoREST interaction domain was found in the amino terminus, which does not contain repressor activity. However, a weaker interaction was noted with the first of two ZNF217 repressor domains that appears to be HDAC dependent. Thus, these results demonstrate that components of the ZNF217 repressor complex make direct contacts with distinct regions of ZNF217.
ZNF217 contains a DNA-binding domain
The presence of multiple zinc-fingers within ZNF217 strongly suggests that it may have DNA-binding activity. To identify a specific binding site, we utilized CAST analysis to determine the DNA-binding specificity of ZNF217. For these experiments, a pool of random oligonucleotides was incubated with recombinant glutathione S-transferase (GST)-ZNFDBD (aa 465-536) encompassing the sixth and seventh zincfingers. This region most likely represents the core DNA-binding domain based on the presence of a canonical linker (TGEKPY). This linker is found in over 100 zinc-finger proteins and crystal structure data have demonstrated that the linker is a critical structural element required for high-affinity DNA binding (ElrodErickson and Pabo, 1999; Iuchi, 2001) . Following several rounds of selection and amplification, the amplified DNA was tested for specific binding to GST-ZNFDBD by electrophoretic mobility shift assay (EMSA) (Figure 4a ). Analysis of multiple clones identified a CRS consisting of a CAGAAYDSTGGW RKW and a core recognition sequence of CAGAAY (Figure 4b ). To confirm that ZNF217 is capable of specific binding to this consensus site, we performed EMSA using GST-ZNFDBD, which indicated that the recombinant GST-ZNFDBD bound specifically to this consensus site as well as a shorter core consensus site consisting of three CAGAAG repeats (Figure 4c ).
ZNF217 binds to and mediates repression of the E-cadherin promoter A preliminary analysis of selected human genes indicated that the CRS is highly conserved within several human promoters including the human E-cadherin proximal promoter. To confirm that ZNF217 is capable of binding the CRS identified within the E-cadherin promoter, EMSA was performed with GST-ZNFDBD using the E-cadherin proximal promoter as well as the minimal E-cadherin CRS. In both cases, a specific shift was observed, suggesting that ZNF217 may target components of the ZNF217 complex to the E-cadherin proximal promoter through sequence-specific DNA binding (Figure 5a ).
To determine if ZNF217 is found on the endogenous E-cadherin promoter in vivo, we used ChIP assays followed by PCR using primers specific to the E-cadherin proximal promoter, or PCR using a set of control primers located 3 kb upstream of the E-cadherin promoter, and demonstrate that ZNF217 is found on the E-cadherin proximal promoter (Figure 5b ). Furthermore, ChIP assays using MCF7 cells transiently transfected with a luciferase reporter plasmid containing the E-cadherin proximal promoter in the presence and absence of the CRS, corresponding to À221/ þ 30 and À203/ þ 30 respectively, indicated that binding of ZNF217 to the E cadherin promoter is dependent on the presence of the CRS (Figure 5c ).
Additional ChIP experiments were also carried out using antibodies raised against several of the ZNF217 complex components. These experiments demonstrate that in addition to ZNF217, CoREST and BHC110/ LSD1 are also bound to the E-cadherin promoter in human MCF-7 cells. To assess whether we could detect a difference in promoter occupancy of the ZNF217 complex at the E-cadherin promoter in E-cadherinpositive (MCF-7) and -negative (MDA-MB-231) cell lines, the ChIPs were repeated using quantitative realtime PCR and a TaqMan probe/primer set that is centred on our identified ZNF217 CRS (Figure 5d ). The results of these ChIP experiments confirm that the major constituents of the ZNF217 complex are indeed found on the region of the E-cadherin promoter that contains our identified ZNF217 CRS in both E-cadherin-positive and -negative cell types (Figure 5d) .
The results of the ChIP experiments were consistent and reproducible for the identified ZNF217 complex components, with the exception of CtBP whose occupancy seemed to be less stable. The variability of CtBP occupancy on the E-cadherin proximal promoter suggests that CtBP may represent a transient component of the ZNF217 complex whose presence is regulated.
To address the functional consequences of ZNF217 binding to the E-cadherin promoter, we used small Figure 4 ZNF217 is a sequence-specific transcription factor. (a) ZNF217 binds DNA in a sequence-specific manner. CAST was performed using the putative core DNA-binding element of ZNF217. (b) Identification of a ZNF217 CRS. Oligonucleotides from the fifth round of CAST were purified using EMSA in the presence of 2 mg of GST-ZNFDBD. The specific band was extracted, amplified and subcloned into pcDNA3 and sequenced. Alignment of sequenced clones demonstrates a consensus sequence of CAGAAYDSTGGWRKW with the core consensus being CAGAAY, where Y represents a C or T, D represents an A, T or G, S represents a C or G, W represents a T or A, R represents an A or G and K represents a T or G. (c) The binding of ZNF217 to its CRS, as demonstrated by EMSA, can be competed away using increasing amounts of cold competitor but not random oligonucleotides (0, Â 100 and Â 500).
interfering RNA (siRNA) to downregulate ZNF217, in conjunction with transient transfection assays using the proximal E-cadherin promoter fused to a luciferase reporter plasmid. Downregulation of ZNF217 resulted in a 2-4-fold increase in reporter activity (Figure 6a) . Conversely, overexpression of ZNF217, but not the control plasmid, repressed a luciferase reporter plasmid containing the proximal promoter of the E-cadherin gene (Figure 6b) . Additionally, when the CRS within the E-cadherin proximal promoter is removed (À203/ þ 30), slightly higher levels of reporter activity were observed in the presence of ZNF217 (Supplemental Figure 1a) . Figure 5 The ZNF217 complex is found on the endogenous E-cadherin promoter. (a) EMSA demonstrates that increasing amounts of GST-ZNFDBD (0-2 mg) bind to the proximal E-cadherin promoter (À308/ þ 30 or À221/ þ 30) and the ZNF217 CRS found within the E-cadherin promoter (E-cad CRS). (b) (Bottom) ChIP demonstrating that ZNF217 complex binds specifically to the E-cadherin proximal promoter but not a region 3 kb upstream (top) in MCF-7 cells (*represents the ZNF217 CRS at À204/À218 and arrows represent primer pairs). (c) Real-time PCR quantification of ChIP experiments performed on MCF7 cells transfected with a luciferase reporter containing the proximal E-cadherin promoter in the absence (À203/ þ 30) or presence (À221/ þ 30) of the identified ZNF217 CRS using primers specific to the reporter luciferase sequence. (d) Real-time PCR quantification of ChIP experiments using antibodies against ZNF217 complex components and primers specific to a 64 bp region of the E-cadherin proximal promoter that contains the ZNF217 CRS demonstrates that components of the ZNF217 complex bind to the region of the E-cadherin proximal promoter containing the ZNF217 CRS in E-cadherin-positive (MCF-7) and -negative (MDA-MB-231) cell lines.
The modest effects on transcription may be due to the presence of the well-characterized repressor elements, the E-boxes, which are located downstream of the CRS within the E-cadherin proximal promoter. Therefore, to investigate the transcriptional effects of the CRS independently of the E-boxes, we inserted a concatamerized version of the E-cadherin sequence containing our identified CRS upstream of a reporter gene driven by the SV40 promoter. These results demonstrate that the CRS is able to confer strong repression to a heterologous promoter (Supplemental Figure 1b) .
To investigate the potential role of ZNF217 in targeting the components of the ZNF217 repressor complex, we transfected combinations of cDNAs with the proximal E-cadherin promoter construct into the E-cadherin-positive MDCK cell line. Interestingly, the individual components, with the exception of ZNF217, do not repress transcription when transfected alone. However, when co-transfected with ZNF217, a greater degree of repression was observed, which was particularly prominent for the transfection involving CoREST and ZNF217 (Figure 6c ). Collectively, these results suggest that ZNF217 may serve as a targeting protein for additional components of the co-repressor complex at the proximal promoter of the endogenous E-cadherin gene.
Discussion
In the present study, we demonstrate that ZNF217 is a transcriptional repressor and map the repression domains to the carboxy-terminus. Utilizing protein purification, in conjunction with mass spectrometry, we have shown that ZNF217 is a constituent of a core complex consisting of CoREST, HDAC2 and BHC110/ LSD1. ZNF217 has been identified as a constituent of several related transcriptional complexes (You et al., 2001; Hakimi et al., 2003; Shi et al., 2003; Lee et al., 2005) . However, in the majority of these studies several other zinc-finger transcription factors, in addition to ZNF217, also co-purified, suggesting that these complexes may be heterogenous in nature and represent multiple complexes. Thus, it is not clear which of the associated proteins specifically associate with ZNF217. We have purified ZNF217 and validated its association with other proteins biochemically, utilizing a protocol that specifically targets the ZNF217 protein. Each of the ZNF217 complex components was identified by mass spectrometry and Western blotting and confirmed with reciprocal immunoprecipitations with the exception of CtBP1, which was not identified by mass spectrometry. However, western blotting, reciprocal immunoprecipitations and overexpression studies clearly indicate that CtBP1 does associate with ZNF217. This interaction is most likely direct, as molecular mapping studies indicate that the carboxy-terminal repressor domain of ZNF217 interacts directly with CtBP1. While this paper was in review, it was demonstrated that ZNF217 can function as a transcriptional repressor and binds to CtBP2 through a PXDLS and RRT domain (Quinlan et al., 2006) .
The ZNF217 complex possesses both HDAC activity and specific H3K4 demethylase activity. The demethylase activity is likely mediated by BHC110/LSD1, which has recently been shown to catalyse the demethylation of mono-or dimethylated lysine 4 on histone H3 (Shi et al., 2004) . H3K4 methylation serves as an important marker for transcriptional activation of genes and is emerging as a key event that may be deregulated in specific forms of cancer (Hamamoto et al., 2004) . The ability to rapidly reverse histone methylation through specific targeting of a demethylase indicates that a dynamic balance between methylation and demethylation may be necessary for the proper coordination of transcription. Consequently, it is conceivable that factors such as ZNF217, which is amplified and overexpressed in many cancer cell lines, could upset this balance resulting in aberrant cell growth.
A second major finding of this study is the identification of a CRS indicating that ZNF217 is a sequencespecific DNA-binding protein. This CRS is found within the proximal promoter of the human E-cadherin gene and we have provided several lines of evidence demonstrating that the E-cadherin gene is a target for ZNF217-mediated repression. Treatment of U2OS cells with ZNF217-specific siRNA relieved repression of a reporter driven by the E-cadherin proximal promoter containing the ZNF217 CRS. Additionally, overexpression of ZNF217 repressed expression of the same reporter in both E-cadherin-positive and -negative cell lines. Importantly, ChIP experiments indicate that several of the core components of the ZNF217 complex are found on a region of the endogenous E-cadherin promoter containing the identified CRS.
The loss of E-cadherin expression is considered a hallmark of epithelial-mesencyhmal transition and has been observed during tumour progression of most carcinomas. At the transcriptional level, several transcription factors have been described as repressors of E-cadherin (Batlle et al., 2000; Cano et al., 2000; Grooteclaes and Frisch, 2000; Comijn et al., 2001; Perez-Moreno et al., 2001; Yang et al., 2004) . However, in all of these cases, binding occurs through specific E-boxes found downstream of the ZNF217 recognition sequence. We have found that the ZNF217 complex occupies the E-cadherin proximal promoter in both E-cadherin-positive and -negative cell lines, suggesting that ZNF217 alone may not be sufficient to fully repress E-cadherin and may require the coexpression of other transcription factors that bind to adjacent regions of the E-cadherin promoter. Alternatively, it is becoming apparent that the specificity of histone-modifying enzymes found as constituents of multiprotein complexes are subject to regulation. For example, recent findings indicate that LSD1 can function as a transcriptional coactivator by binding to the androgen receptor, which alters the specificity of LSD1 from demethylation of H3K4 to H3K9 (Metzger et al., 2005) . Thus, depending on the specific interacting partners, LSD1 action may result in gene repression or activation. Finally, the various repressors of E-cadherin may have specific roles in different tumours and cell types, or at specific stages of tumour progression, thereby contributing to the cellular heterogeneity found in many tumours. In agreement with this concept, it has been noted that E-cadherin expression is highly dynamic; after initial silencing of E-cadherin in primary carcinomas, Ecadherin is frequently re-expressed at secondary sites of metastasis (Takeichi, 1993; Bukholm et al., 2000) . Our results highlight a potentially novel role for CoREST in tumour progression. Earlier studies have established that CoREST binds to the RE1 silencing transcription factor (REST) and is involved primarily in silencing of neuron-specific genes in non-neuronal cells (Andres et al., 1999; Grimes et al., 2000; You et al., 2001) . Interestingly, Lee et al. (2005) have demonstrated a functional association between COREST and BHC110/ LSD1. COREST was shown to stimulate BHC110/ LSD1 activity by promoting the demethylation of nucleosomal substrates, suggesting that the functional activity of COREST and that ofBHC110/LSD1 are tightly linked.
Overexpression of ZNF217 has been noted in multiple cancer cell lines and tumours and may have a number of functional consequences. ZNF217 overexpression may inappropriately bind to target genes containing lower affinity binding sites. Consequently, transcriptionactivating methyl H3K4 and/or acetyl marks may be removed by the ZNF217 complex, resulting in aberrant gene repression and possibly tumorigenesis. ZNF217 overexpression may indirectly affect gene regulation by disrupting the function of other transcription factors that, under normal conditions, require co-repressors such as CoREST. While this paper was in preparation, ZNF217 overexpression was demonstrated to function in the suppression of apoptosis associated with chemotherapeutic treatment and increased phosphorylation of Akt, further demonstrating its importance in cancer progression (Huang et al., 2005) .
In summary, the results presented in this study establish ZNF217 as a transcriptional repressor protein and provide potentially new therapeutic cancer targets. Indeed, the intriguing identification of CoREST as a component of the ZNF217 complex suggests a potential role of this co-repressor in cancer. The identification of novel ZNF217 complex targets will be invaluable in gaining a better understanding of the role that ZNF217 plays in tumorigenesis.
Materials and methods
Generation of ZNF217 antibody A rabbit polyclonal antibody recognizing ZNF217 was generated against a recombinant HIS-tagged protein encoding the carboxy-terminus portion of ZNF217 (aa 528-761). The antibody was affinity purified using the immunoreactive antigen according to standard procedures.
Purification of ZNF217 complex
For a detailed description of the purification, see Supplementary Information.
Co-immunoprecipitations MCF-7 cells were transfected with cDNAs encoding HA-tagged ZNF217 alone or with HIS-tagged CoREST or FLAG-tagged CtBP1 using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Cells were harvested and lysed 48 h post-transfection, incubated with affinity resin and washed extensively. Immunoprecipitated proteins were analysed by SDS-PAGE and Western blotting. To confirm components of the ZNF217 complex, approximately 1 mg of HeLa nuclear extracts was immunoprecipitated with the indicated antibodies, washed extensively and the bound proteins were analysed by SDS-PAGE and Western blotting.
Deacetylase assay HDAC assays were performed as described previously (Dellaire et al., 2002) .
Methylation and demethylation assays
Biotin-labelled histone H3 peptides (aa 1-21; Upstate, Temecula, CA, USA) were methylated in vitro with [ 3 H]SAM using recombinant SET9 according to the manufacturer's protocol (Upstate Biotechnology). A 250 ng portion of methylated biotin-histone H3 peptide was added to 250 ml of demethylase buffer (50 mM Tris (pH 8.3), 50 mM KCl, 5 mM MgCl 2 and 5% glycerol) and incubated with MagnaSphere Streptavidin beads (Promega, Madison, WI, USA) for 1 hat 41C. The radiolabelled-bound histone H3 peptides were washed four times with 1 ml of demethylase buffer and resuspended in 20 ml demethylase buffer containing 1 mg bovine serum albumin (BSA), as a control, or increasing amounts of ZNF217 affinity-purified complex. The reaction was incubated at 371C for 2 h while mixing at 1400 r.p.m. The released [ In vitro mapping of ZNF217 interactions CtBP1 and CoREST GST fusion proteins for CtBP1 and CoREST were purified on glutathione agarose beads following standard procedures. Briefly, ZNF217 deletion mutants were radiolabelled in vitro using [ 35 S]methionine and incubated with GST-CoREST or GST-CtBP1 immobilized on glutathione agarose. The bound proteins were washed extensively, resolved by SDS-PAGE and visualized using a phosphoimager.
CAST and EMSA assays CAST was performed as previously described (Ausubel, 2002) with modifications as indicated in Supplementary Information.
ChIP
ChIP assays were performed using standard procedures, as detailed in Supplementary Information.
Luciferase assays
Cells were transfected using Lipofectamine 2000 (Invitrogen). Twenty-four hours post-transfection, the cells were treated with 0 or 300 nM TSA for 24 h and then harvested. Luciferase activity was determined by using a standard luciferase assay (Promega). For the experiments determining the effects of ZNF217 on transcription of the E-cadherin promoter, a region from À221 to þ 30 of the E-cadherin promoter was inserted into the pGL2 basic vector (Promega).
siRNA transfections
Human U2OS cells were transfected in 24-well plates with 250 ng luciferase reporter and 10 pmol ZNF217 siRNA (SMART pool, Dharmacon, Lafeyette, CO, USA) or control siRNA (siCONTROL Non-Targeting siRNA #1, Dharmacon), using Lipofectamine 2000 or Oligofectamine (Invitrogen). Seventy-two hours post-transfection, the cells were harvested in passive lysis buffer (Promega) and luciferase activity was determined by using a standard luciferase assay (Promega).
